Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Beishuizen, E. D.
Right arrow Articles by Huisman, M. V.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Beishuizen, E. D.
Right arrow Articles by Huisman, M. V.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes Care 28:1263-1264, 2005
© 2005 by the American Diabetes Association, Inc.

Letters: Comments and Responses

Two-Year Statin Therapy Does Not Alter the Progression of Intima-Media Thickness in Patients With Type 2 Diabetes Without Manifest Cardio-vascular Disease

Response to Cicero et al.

Edith D. Beishuizen, MD1, Marcel A. van de Ree, MD, PHD2, J. Wouter Jukema, MD, PHD3, Jouke T. Tamsma, MD, PHD1 and Menno V. Huisman, MD, PHD1

1 Department of General Internal Medicine, Leiden University Medical Center, Leiden, the Netherlands
2 Department of Internal Medicine, Diakonessenhuis, Utrecht, the Netherlands
3 Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands

Address correspondence to E.D. Beishuizen, Department of General Internal Medicine, C1-R41, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, Netherlands. E-mail: e.d.beishuizen@lumc.nl

The first 20% of the full text of this article appears below.

We thank Cicero et al. (1) for their comments on our article (2). We measured intima-media thickness (IMT) at baseline and after 1 and 2 years. Thus, the assertion by Cicero et al. that we "should have concluded that 15.4 months of treatment with 0.4 mg cerivastatin...is not efficacious in reducing IMT progression in type 2 diabetic subjects" cannot, in our view, be drawn from the data as gathered. Although the level of LDL cholesterol was significantly higher during 20-mg simvastatin treatment compared with 0.4-mg . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2005 by the American Diabetes Association.